Head-to-head comparison of the fully-automated Elecsys® Anti-SARS-CoV-2.
with the EDI TM IgM and IgG ELISAs for the detection of SARS-CoV-2 antibodies.
Antibodies were measured in COVID-19 patients, healthy blood donors and ICU patients.
Our findings indicate very high sensitivity/specificity for the Anti-SARS-CoV-2 assay.
We found acceptable agreement with the EDI TM IgM and IgG ELISAs.
Here, we report on a head-to-head comparison of the fully-automated Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI TM enzyme linked immunosorbent assays (ELISA) for the detection of SARS-CoV-2 antibodies in human plasma.
SARS-CoV-2 antibodies were measured with the Elecsys® assay and the EDI TM ELISAs (IgM and IgG) in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used.
In COVID-19 patients, the percentage of positive results rose with time from symptom onset, peaking to positivity rates after 15-22 days of 100% for the Elecsys® assay, of 94% for the EDI TM IgM-ELISA and of 100% for the EDI TM IgG ELISA. In the 104 blood samples, the agreement between positive/negative classifications of the Elecsys® assay and the EDI TM ELISAs (IgM or IgG) was 90%. The false positivity rates in the healthy blood donors and the ICU patients were <1% for the Elecsys® assay and <3% for the EDI TM ELISAs.